Physician profile
Christopher Tran
NPI 1790382760
$2,395.73
in general payments reported to CMS, 2019-2025
25 companies · $522 in 2025
The $522 reported for 2025 was more than what 76% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2022: $580 · 2023: $634 · 2024: $380 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $510.40 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $341.45 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $269.36 | 2021-2025 | |
| Lilly USA, LLC | $207.63 | 2021-2024 | Mounjaro, Emgality, Jardiance |
| Nestle Healthcare Nutrition INC. | $175.94 | 2021-2023 | |
| Pfizer INC. | $140.65 | 2021-2025 | |
| Abbvie INC. | $91.20 | 2021 | |
| Glaxosmithkline, LLC. | $74.15 | 2022-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $60.49 | 2022 | |
| Sanofi-Aventis U.S. LLC | $58.86 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $53.68 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $53.64 | 2022-2023 | Livalo, Seglentis |
| E.R. Squibb & Sons, L.L.C. | $49.38 | 2022-2023 | Eliquis |
| Abbott Laboratories | $46.02 | 2022-2024 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $45.20 | 2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.06 | 2021-2023 | Jardiance |
| Dynavax Technologies Corporation | $26.61 | 2023 | Heplisav-B |
| Corcept Therapeutics | $21.45 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.01 | 2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $19.95 | 2024 | Gvoke Hypopen |
| Eisai INC. | $19.40 | 2021 | |
| Exact Sciences Corporation | $18.82 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $18.69 | 2022 | |
| Baxter Healthcare | $14.94 | 2024 | Hillrom - Monarch Airway Clearance System |
| Convatec INC. | $14.75 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.